Patent ID: 8404270

Claim:
A method of treating an ocular disease in a subject using Fluocinolone Acetonide, wherein the incidence of intraocular pressure lowering surgery at 1 year or more after treatment is less than 10%, comprising injecting at least one free-floating non-bioerodable intravitreal insert comprising a dosage of Fluocinolone Acetonide into an eye of the subject such that the intravitreal insert settles near the base of the eye, wherein the intravitreal insert is configured to release Fluocinolone Acetonide in a controlled manner over a time period of at least one year, wherein the dosage of the at least one intravitreal insert is from about 0.1 μg/day to about 0.45 μg/day for at least 24 months.